Leach Amanda J, Wigger Christine, Beissbarth Jemima, Woltring Donna, Andrews Ross, Chatfield Mark D, Smith-Vaughan Heidi, Morris Peter S
Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Int J Pediatr Otorhinolaryngol. 2016 Jul;86:224-32. doi: 10.1016/j.ijporl.2016.05.011. Epub 2016 May 11.
This study aims to monitor the prevalence of suppurative otitis media in remote Indigenous communities after introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in October 2011. We previously reported a decline in suppurative OM following replacement of PCV7 by 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) in October 2009.
We continued regular surveillance in remote Indigenous communities between February 2010 and August 2013. This analysis reports the general health, otitis media (OM), nasopharyngeal (NP) carriage and middle ear microbiology in children less than 36 months of age who received a primary course of at least two doses of PHiD-CV10 or PCV13, and not more than one dose of another pneumococcal vaccine.
Mean ages of 511 PHiD-CV10- and 140 PCV13-vaccinated children were 19 and 13 months, respectively. Most children received 3-dose non-mixed PCV schedules. At the time of assessment, general health was poor and prevalence of risk factors was high in both groups: overall, around 14% of children had scabies, 20% had impetigo, 59% had runny nose and 39% had cough. Average household size was 8 persons, and 60% of the mothers smoked. Bilaterally normal middle ears were detected in 10% and 7%, respectively. OM with effusion (OME), almost all bilateral, was diagnosed in 52% and 50%, any suppurative OM (acute OM or any tympanic membrane perforation [TMP]) in 37% and 41%, and TMP in 14% and 12%, respectively. Children in the PCV13 group had significantly less NP carriage of combined Streptococcus pneumoniae (Spn) and non-typeable Haemophilus influenzae (NTHi) (62% versus 51%) but significantly more polymicrobial (Spn and NTHi) middle ear cultures (12% versus 43%), and significantly less Staphylococcus aureus-positive middle ears (40% versus 7%). Although NP carriage of pneumococcal serotype 19A was low in the PCV13 group, serotypes 19F and 23F persist.
The general health, particularly ear health, of little children in remote Australian Indigenous communities remains in crisis. In particular, transition to PCV13 did not show substantial further improvement in ear health. Possible vaccine-related differences in microbiology, including potential beneficial effects of PHiD-CV10 on NTHi infection, need to be further evaluated in randomised trials.
本研究旨在监测2011年10月引入13价肺炎球菌结合疫苗(PCV13)后,偏远原住民社区化脓性中耳炎的患病率。我们之前曾报道,2009年10月用10价肺炎球菌-流感嗜血杆菌蛋白D结合疫苗(PHiD-CV10)替代PCV7后,化脓性中耳炎的发病率有所下降。
我们在2010年2月至2013年8月期间,继续对偏远原住民社区进行定期监测。本分析报告了年龄小于36个月、接受至少两剂PHiD-CV10或PCV13的初级疗程且接种不超过一剂其他肺炎球菌疫苗的儿童的总体健康状况、中耳炎(OM)、鼻咽(NP)携带情况及中耳微生物学情况。
接种PHiD-CV10的511名儿童和接种PCV13的140名儿童的平均年龄分别为19个月和13个月。大多数儿童接受了3剂非混合PCV接种方案。在评估时,两组儿童的总体健康状况均较差,危险因素患病率较高:总体而言,约14%的儿童患有疥疮,20%的儿童患有脓疱病,59%的儿童流鼻涕,39%的儿童咳嗽。平均家庭规模为8人,60%的母亲吸烟。双侧中耳正常的比例分别为10%和7%。诊断为中耳积液(OME)的比例分别为52%和50%(几乎均为双侧),任何化脓性中耳炎(急性中耳炎或任何鼓膜穿孔[TMP])的比例分别为37%和41%,鼓膜穿孔的比例分别为14%和12%。PCV13组儿童鼻咽部肺炎链球菌(Spn)和非分型流感嗜血杆菌(NTHi)的联合携带率显著较低(62%对51%),但中耳多微生物(Spn和NTHi)培养阳性率显著较高(12%对43%),金黄色葡萄球菌阳性中耳的比例显著较低(40%对7%)。尽管PCV13组肺炎球菌19A血清型的鼻咽携带率较低,但19F和23F血清型仍然存在。
澳大利亚偏远原住民社区幼儿的总体健康状况,尤其是耳部健康状况仍然处于危机之中。特别是,向PCV13的过渡并未显示出耳部健康状况有实质性的进一步改善。微生物学方面可能存在的疫苗相关差异,包括PHiD-CV10对NTHi感染的潜在有益作用,需要在随机试验中进一步评估。